# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week ...
Intelgenx Technologies (OTC:IGXT) reported quarterly losses of $(0.01) per share. This is a 50 percent increase over losses of ...
IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it and Tilray Brands ...
IntelGenx Technologies Corp. (TSX: IGX) (OTC: IGXT), a drug delivery company focused on the development and manufacturing of ph...
Intelgenx Technologies (OTC:IGXT) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last y...
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics rece...
IntelGenx Technologies Corp. (OTC: IGXT) reported on Thursday a 32% decrease in total revenues for the first quarter of 2023, a...
Intelgenx Technologies (OTC:IGXT) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last y...
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsui...